tetano
Editor, Senior Moderator
Viruses
. 2021 Oct 5;13(10):2003.
doi: 10.3390/v13102003.
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
Stefan Glöckner[SUP] 1 [/SUP], Franziska Hornung[SUP] 1 [/SUP], Michael Baier[SUP] 1 [/SUP], Sebastian Weis[SUP] 2 3 4 [/SUP], Mathias W Pletz[SUP] 2 [/SUP], Stefanie Deinhardt-Emmer[SUP] 1 5 [/SUP], Bettina Löffler[SUP] 1 [/SUP], The CoNAN Study Group
Affiliations
Abstract
Humoral immunity after infection or after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been attributed a key part in mitigating the further transmission of the virus. In this study, we used a commercial anti-Spike immunoglobulin G (S-IgG) assay and developed a cell culture-based neutralization assay to understand the longitudinal course of neutralizing antibodies in both SARS-CoV2 infected or vaccinated individuals. We show that even more than one year after infection, about 78% of observed study participants remained seropositive concerning S-IgG antibodies. In addition, the serum of the individuals had stable neutralization capacity in a neutralization assay against a SARS-CoV-2 patient isolate from March 2020. We also examined volunteers after either homologous BNT162b2 prime-boost vaccination or heterologous AZD1222 prime/mRNA-based booster vaccination. Both the heterologous and the homologous vaccination regimens induced higher levels of neutralizing antibodies in healthy subjects when compared to subjects after a mild infection, showing the high effectiveness of available vaccines. In addition, we could demonstrate the reliability of S-IgG levels in predicting neutralization capacity, with 94.8% of seropositive samples showing a neutralization titer of ≥10, making it a viable yet cheap and easy-to-determine surrogate parameter for neutralization capacity.
Keywords: COVID-19; SARS-CoV-2; antibodies; immunity; neutralization; serology; vaccination.
. 2021 Oct 5;13(10):2003.
doi: 10.3390/v13102003.
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
Stefan Glöckner[SUP] 1 [/SUP], Franziska Hornung[SUP] 1 [/SUP], Michael Baier[SUP] 1 [/SUP], Sebastian Weis[SUP] 2 3 4 [/SUP], Mathias W Pletz[SUP] 2 [/SUP], Stefanie Deinhardt-Emmer[SUP] 1 5 [/SUP], Bettina Löffler[SUP] 1 [/SUP], The CoNAN Study Group
Affiliations
- PMID: 34696428
- DOI: 10.3390/v13102003
Abstract
Humoral immunity after infection or after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been attributed a key part in mitigating the further transmission of the virus. In this study, we used a commercial anti-Spike immunoglobulin G (S-IgG) assay and developed a cell culture-based neutralization assay to understand the longitudinal course of neutralizing antibodies in both SARS-CoV2 infected or vaccinated individuals. We show that even more than one year after infection, about 78% of observed study participants remained seropositive concerning S-IgG antibodies. In addition, the serum of the individuals had stable neutralization capacity in a neutralization assay against a SARS-CoV-2 patient isolate from March 2020. We also examined volunteers after either homologous BNT162b2 prime-boost vaccination or heterologous AZD1222 prime/mRNA-based booster vaccination. Both the heterologous and the homologous vaccination regimens induced higher levels of neutralizing antibodies in healthy subjects when compared to subjects after a mild infection, showing the high effectiveness of available vaccines. In addition, we could demonstrate the reliability of S-IgG levels in predicting neutralization capacity, with 94.8% of seropositive samples showing a neutralization titer of ≥10, making it a viable yet cheap and easy-to-determine surrogate parameter for neutralization capacity.
Keywords: COVID-19; SARS-CoV-2; antibodies; immunity; neutralization; serology; vaccination.